Thermo LabSystems has been named among the top ten bioinformatics companies in a recent Frost and Sullivan analysis report on the US bioinformatics market
The Frost & Sullivan report refers to Thermo Labsystems's leading product in bioinformatics - Nautilus LIMS for biotechnology applications.
The company's top ten ranking was confirmed in a Financial Times article on Bioinformatics and Big Biology of November 27.
Gordon Logan, managing director of Thermo LabSystems, commented: "This is a highly significant acknowledgement that will no doubt be very well received by our employees and customers alike, particularly since we have only entered the market in a strategic way over the last 18 months.
I believe it reflects the rapid adoption of Nautilus among many of the world's most progressive biotechnology companies, together with our ability to support customers on a truly global basis".
The report by Frost & Sullivan reveals the bioinformatics industry generated revenues totaling $1.38 billion in 2000; a figure which is expected to reach $6.9 billion in 2007.
Frost & Sullivan forecasts revenues from markets for hardware and software for genetic sequence data generation, stand-alone genetic sequence analysis systems, and genetic sequence data management systems will continue to show significant growth through 2007.
Thermo LabSystems claims Nautilus offers the bio-research community new levels of user empowerment, sample traceability and instrument integration.
The latest version of the product offers powerful data management capabilities for techniques including cDNA library management, SNP scoring, sequencing and genotyping. Nautilus also features advanced functionality for micro-array and microtiter plate handling and sequencer integration.
Nautilus benefits customers in biotechnology and drug discovery through the extraction of information and knowledge from the vast data volumes generated in high throughput experimentation and screening.
Nautilus features a complete suite of tools to enable customers to address compliance with US FDA Ruling 21 CFR Part 11, which concerns electronic records and signatures.
